Journal of Hypertension · 2004 · 97 citations · 53 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyClinical CardiologyInflammationCardiac PharmacotherapyCardiovascular DiseaseCardiovascular PharmacodynamicsCardiovascular PharmacologyHypertension PharmacotherapyIschemic Heart DiseaseAngiotensin-converting Enzyme Inhibitory PeptidesAntihypertensive PharmacologyCollagen DegradationCollagen Degradation InhibitionCollagen Type I DepositionRenin-angiotensin System InhibitorsType I Collagen DepositionType I Collagen Production
OBJECTIVE: N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a potent natural inhibitor of hematopoietic stem cell proliferation which is degraded mainly by angiotensin-converting enzyme (ACE). In vitro, Ac-SDKP inhibits collagen production by cardiac fibroblasts; while in vivo it blocks collagen deposition in the left ventricle (LV) of rats with hypertension or myocardial infarction (MI). In addition, it reportedly prevents and reverses macrophage infiltration in the LV of rats with MI. We tested the hypothesis that when Ac-SDKP is infused at doses that cause plasma concentrations similar to those observed after ACE inhibition, it mimics the anti-inflammatory and antifibrotic effects of ACE inhibitors (ACEi) in the heart, and, further, that these effects are independent of changes in blood pressure. DESIGN AND METHODS: Rats were divided into five groups: (1) controls, (2) Ang II (750 microg/kg per day, s.c.), (3) Ang II + captopril (100 mg/kg per day in drinking water), (4) Ang II + Ac-SDKP (400 microg/kg per day, s.c.), and (5) Ang II + Ac-SDKP (800 microg/kg per day, s.c.). We measured LV cell proliferation, inflammatory cell infiltration, cytokine expression, hypertrophy and fibrosis. RESULTS: Plasma Ac-SDKP was five-fold higher in rats given ACEi and four- and ten-fold higher in rats given 400 and 800 microg/kg per day Ac-SDKP, respectively. ACEi significantly decreased Ang II-induced cell proliferation (Ki-67), LV macrophage/mast cell infiltration, transforming growth factor-beta, connective tissue growth factor and collagen deposition without affecting hypertension, LV hypertrophy or myocyte cross-sectional area, and these effects were mimicked by exogenous Ac-SDKP (400 microg/kg per day) which raised plasma Ac-SDKP to levels similar to ACEi. BP was not decreased by either ACEi or Ac-SDKP. CONCLUSIONS: We concluded that Ac-SDKP may be an important mediator of the anti-inflammatory and antifibrotic effects of ACEi in hypertension independent of its hemodynamic effects.
53
C Schlüter, M. Duchrow, Claudia Wohlenberg et al. · The Journal of Cell Biology · 1993 · 776 citations · Full text
Xiaoping Yang, Victor G. Sharov, Omar Nass et al. · Journal of Clinical Investigation · 1997 · 604 citations · Full text
Medicine, Cardiology, Pharmacology +17
Collagen remodeling after myocardial infarction in the rat heart.
Jack P.M. Cleutjens, M. J. Verluyten, J F Smiths et al. · PubMed · 1995 · 553 citations
Medicine, Biochemistry, Cardiology +12